By Jonathan Stempel (Reuters) - A U.S. appeals court on Wednesday upheld two patents for Amgen Inc's multibillion-dollar rheumatoid arthritis drug Enbrel in a defeat for Novartis AG, which has been trying to sell its own version.The 2-1 decision by the U.S. Federal Circuit Court of Appeals in Washington, D.C. gives Amgen 31 years of exclusive rights to Enbrel, with protection for the patents extending to November 2028 and April 2029.